Compare · AMAG vs DRNA
AMAG vs DRNA
Side-by-side comparison of AMAG Pharmaceuticals, Inc. (AMAG) and Dicerna Pharmaceuticals, Inc. (DRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMAG and DRNA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for AMAG).
- Company
- AMAG Pharmaceuticals, Inc.
- Dicerna Pharmaceuticals, Inc.
- Price
- -
- $38.23+0.61%
- Market cap
- -
- $2.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 14
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest AMAG
- Landsdowne Labs Names Bryan Laulicht CEO
- Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
- Covis Group Completes Acquisition of AMAG Pharmaceuticals
- Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Contango Oil & Gas Company, Eaton Vance Corp., MobileIron, Inc., Seacoast Commerce Banc Holdings, Perceptron, Inc., Standard AVB Financial Corp., Virginia National Bankshares Corporation and Virtusa Corporation
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - VRTU, AMAG, EV, CBMG
- Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Eaton Vance Corp., MobileIron, Inc., and Seacoast Commerce Banc Holdings
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company